Imelciment Biosimilar - Research Grade

Human

vixticibart

>1mg/ml

half-IG G4 - kappa / h-CH2-CH3

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of Imelciment (originator code REGN-9035), supplied for research use only and not for human or veterinary use. Notably, Imelciment is itself an anti-idiotype / reversal agent: its target is not a conventional cell-surface antigen but the investigational NPR1-agonist antibody vixticibart (REGN5381). The analog is therefore built to recapitulate binding to vixticibart, letting laboratories reproduce the drug/reversal-agent pairing in vitro. It is presented as a half-IgG4-kappa (h-CH2-CH3) format consistent with an engineered anti-idiotype binder. Because it is a defined recombinant reagent, it is useful as an assay control, a capture/detection tool for vixticibart, and a neutralizing counter-reagent in binding and functional studies. It is offered at research grade with low endotoxin (typically <1 EU/mg research grade, <0.5 EU/mg ultra-low) and can be supplied in bulk milligram-to-gram quantities and as an in-vivo-standard-grade preparation for preclinical modeling. It is expressly not the clinical drug and carries no therapeutic claims. The nominal target here is vixticibart (REGN5381), an investigational human IgG4-kappa monoclonal antibody that acts as an allosteric agonist of natriuretic peptide receptor 1 (NPR1, also called NPR-A / GC-A). NPR1 is a single-pass, membrane-bound receptor guanylyl cyclase that is physiologically activated by atrial and B-type natriuretic peptides (ANP, BNP) to raise intracellular cGMP, driving vasodilation, natriuresis and diuresis. Vixticibart binds the NPR1 extracellular domain and stabilizes an active-like conformation, increasing cGMP output independently of, and additively with, endogenous peptides; it is selective for NPR1 over NPR2 and NPR3. Imelciment binds vixticibart itself, functioning as an anti-idiotype reversal agent intended to neutralize the agonist's activity. Understanding NPR1 signaling is thus central to interpreting how this reagent pair behaves.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Imelciment biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Imelciment biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Imelciment biosimilar target?

A: It is a non-therapeutic biosimilar of Imelciment used as a binding and neutralization reagent against vixticibart; for research use only.